New drug combo aims for long remission in untreated CLL patients
NCT ID NCT04458610
First seen Jan 13, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study tests whether combining zanubrutinib (a BTK inhibitor) with rituximab (an antibody) can help people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma achieve a lasting remission after stopping treatment. About 60 participants will receive the combination and then stop zanubrutinib to see if they remain cancer-free for at least 6 months without further therapy. The goal is to control the disease and reduce the need for continuous medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.